Sinotherapeutics Inc. (SHA:688247)

Sinotherapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	249.1	225.79	641.79	763.15	511.66	434.17
Short-Term Investments	-	-	107.21	44.09	-	-
Trading Asset Securities	516.44	507.74	-	-	-	-
Cash & Short-Term Investments	765.54	733.53	749	807.23	511.66	434.17
Cash Growth	2.40%	-2.07%	-7.21%	57.77%	17.85%	68.23%
Accounts Receivable	94.51	110.97	78.47	71.27	44.09	35.84
Other Receivables	3.71	0.3	0.57	-	-	10.54
Receivables	98.22	111.27	79.04	71.27	44.09	46.38
Inventory	90.17	102.42	84.61	29.38	40.43	41.81
Other Current Assets	19.31	29.1	39.36	45.83	22.66	23.64
Total Current Assets	973.24	976.32	952.01	953.71	618.83	546
Property, Plant & Equipment	358.8	344.34	271.41	255.92	115.09	105.72
Long-Term Investments	65.79	64.42	64.2	49.1	69.99	7.86
Goodwill	18.39	18.39	18.39	18.39	-	-
Other Intangible Assets	16.65	21.65	27.59	32.47	41.16	51.58
Long-Term Deferred Tax Assets	18.54	19.33	14.29	16.45	16.08	14.44
Long-Term Deferred Charges	0.55	0.92	1.21	1.99	3.15	3.81
Other Long-Term Assets	4.36	7.94	12.54	4.3	1.5	9.39
Total Assets	1,456	1,453	1,362	1,332	865.81	738.8
Accounts Payable	20.64	16.75	13.34	8.42	8.01	5.39
Accrued Expenses	9	26.49	14.69	11.58	14.19	32.15
Current Portion of Leases	0.02	0.01	0.06	0.32	0.78	-
Current Income Taxes Payable	4.32	6.97	1.28	0.45	7.85	-
Current Unearned Revenue	28.49	30.44	48.01	56.8	46.78	95.51
Other Current Liabilities	17.21	22.54	13.33	12.47	11.92	9.48
Total Current Liabilities	79.69	103.19	90.72	90.05	89.52	142.54
Long-Term Leases	-	-	0.02	1.2	3.66	-
Long-Term Unearned Revenue	66.36	74.72	58.09	61.12	64.62	30.93
Long-Term Deferred Tax Liabilities	2.29	2.39	2.53	2.68	2.82	2.96
Total Liabilities	148.34	180.3	151.36	155.05	160.62	176.42
Common Stock	453.34	453.34	453.34	453.34	408	408
Additional Paid-In Capital	512.94	513.57	512.89	512.89	179.23	171.29
Retained Earnings	377.84	342.22	244.16	211.19	118.26	-16.66
Treasury Stock	-36.13	-36.13	-	-	-	-
Comprehensive Income & Other	-0.01	-	-0.13	-0.15	-0.31	-0.26
Shareholders' Equity	1,308	1,273	1,210	1,177	705.19	562.38
Total Liabilities & Equity	1,456	1,453	1,362	1,332	865.81	738.8
Total Debt	0.02	0.01	0.09	1.52	4.44	-
Net Cash (Debt)	765.52	733.53	748.92	805.71	507.22	434.17
Net Cash Growth	2.40%	-2.05%	-7.05%	58.85%	16.82%	68.23%
Net Cash Per Share	1.64	1.61	1.59	1.91	1.24	1.06
Filing Date Shares Outstanding	449	449	449.15	453.34	408	408
Total Common Shares Outstanding	449	449	453.34	453.34	408	408
Working Capital	893.55	873.13	861.29	863.66	529.31	403.47
Book Value Per Share	2.91	2.84	2.67	2.60	1.73	1.38
Tangible Book Value	1,273	1,233	1,164	1,126	664.02	510.79
Tangible Book Value Per Share	2.84	2.75	2.57	2.48	1.63	1.25
Buildings	-	216.23	211.68	54.29	52.41	45.57
Machinery	-	183.49	160.89	145.6	135.93	117.73
Construction In Progress	-	80.75	15.35	153.61	4.68	9.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.